Motivations for paediatric vaccine trial participation

• Published in: Current controlled trials in cardiovascular medicine 2023-09, Vol.24 (1), p.574-574, Article 574
• Main Authors: Hillson, Kushalinii, Kantor, Jonathan, Pinto, Marta Valente, Pollard, Andrew J, Kelly, Dominic, Vanderslott, Samantha
• Format: Article
• Language: English
• Subjects: Analysis; Children; Clinical trials; Courthouses; COVID-19 vaccines; Data analysis; Data collection; Health aspects; Health behavior; Letter; Pandemics; Participation; Pediatrics; Recruiting; Whooping cough
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-023-07597-2

For our study on trial motivations, 110 surveys were sent out and 81 responded (73·6% response rate). P-values are for two-sample t-tests, without a correction for multiple comparisons Overall (n = 81) Prior Trial Experience (n = 16) No Prior Trial Experience (n = 65) P value Direct benefits to child  Vaccine access—protective 28 (34·6%) 4 (25·0%) 24 (36·9%) 0·38  Paediatrician access 39 (48·15%) 6 (37·5%) 33 (51·6%) 0·35  Immunisations at home 67 (82·7%) 10 (62·5%) 57 (87·7%) 0·02  GP appointments difficult 7 (8·64%) 1 (6·25%) 6 (9·23%) 0·71  Safer to receive vaccines at home 33 (40·74%) 5 (31·25%) 28 (43·08%) 0·39 Altruism/ societal benefits  Improve health of children 79 (97·53%) 16 (100%) 63 (96·92%) 0·48  Scientific progress 80 (98·77%) 16 (100%) 64 (98·46%) 0·62  Others view positively 21 (25·93%) 6 (37·50%) 15 (23·08%) 0·24  Friends/ family positive reaction 57 (70·37%) 10 (62·50%) 47 (72·31%) 0·45 Clinical trial experience  Wanted trial experience 40 (49·38%) 7 (43·75%) 33 (50·77%) 0·62  COVID changed my view 23 (28·40%) 6 (37·50%) 17 (26·15%) 0·37 Pertussis-Specific Concerns  Comforted: vaccine previously approved in UK 77 (95·06%) 16 (100%) 61 (93·85%) 0·31  Comforted: vaccine approved by WHO 78 (96·30%) 16 (100%) 62 (95·38%) 0·39  Side effects worth improved efficacy 79 (97·53%) 15 (93·75%) 64 (98·46%) 0·28  Worried re severe reaction 14 (7·28%) 2 (12·50%) 12 (18·46%) 0·58  Worried about long term health effects 1 (1·23%) 0 (0%) 1 (1·54%) 0·62 This survey has limitations, being an unvalidated survey instrument, the reliance on self-report, and the inability to ascertain motivations among those who declined to participate. SV conceptualised and designed the survey, data collection and validation, literature search, data analysis and provided the overall supervision of the manuscript writing.